Wyeth (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Wyeth" in English language version.

refsWebsite
Global rank English rank
1st place
1st place
low place
low place
4th place
4th place
low place
low place
low place
low place
7th place
7th place
1,333rd place
957th place
954th place
4,563rd place
1,303rd place
808th place
99th place
77th place
54th place
48th place
3,174th place
2,751st place
447th place
338th place
774th place
716th place
412th place
266th place
2,112th place
4,947th place
low place
low place
low place
low place
low place
8,921st place
49th place
47th place
712th place
526th place
197th place
356th place

adcreview.com

bloomberg.com

businessweek.com

corporate-ir.net

phx.corporate-ir.net

fda.gov

fiercepharma.com

forbes.com

fundinguniverse.com

guardian.co.uk

marketwatch.com

newscientist.com

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Centers for Disease Control and Prevention (CDC) (November 14, 1997). "Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997". Morbidity and Mortality Weekly Report. 46 (45): 1061–1066. PMID 9385873.
  • Bross, P. F.; Beitz, J.; Chen, G.; Chen, X. H.; Duffy, E.; Kieffer, L.; Roy, S.; Sridhara, R.; Rahman, A.; Williams, G.; Pazdur, R. (June 7, 2001). "Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia". Clinical Cancer Research. 7 (6): 1490–1496. PMID 11410481. Retrieved August 14, 2024.
  • Sorokin, P. (June 7, 2001). "Sorokin P. Mylotarg approved for patients with CD33+ acute myeloid leukemia". Clinical Journal of Oncology Nursing. 4 (6): 279–280. PMID 11899326. Retrieved August 14, 2024.

nytimes.com

query.nytimes.com

nytimes.com

  • Andrew pollack (June 14, 2010). "Awaiting the Genome Payoff". The New York Times. Retrieved December 26, 2010. "If on the first day we had discovered a new molecular target, it's still going to take 15 to 20 years to make the drug," said Robert R. Ruffolo Jr., who ran research and development at Wyeth until 2008.

pfizer.com

pfizerah.com

pharmalot.com

plos.org

speakingofmedicine.plos.org

reuters.com

rp-online.de

theage.com.au

web.archive.org

wyeth.com